- Home
- RMBI vs KLRS Comparison
RMBI vs KLRS Comparison
Compare RMBI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMBI
- KLRS
- Stock Information
- Founded
- RMBI 1887
- KLRS 2019
- Country
- RMBI United States
- KLRS United States
- Employees
- RMBI N/A
- KLRS N/A
- Industry
- RMBI Major Banks
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMBI Finance
- KLRS Health Care
- Exchange
- RMBI Nasdaq
- KLRS Nasdaq
- Market Cap
- RMBI 148.9M
- KLRS 129.0M
- IPO Year
- RMBI 2019
- KLRS N/A
- Fundamental
- Price
- RMBI $14.25
- KLRS $3.25
- Analyst Decision
- RMBI
- KLRS Buy
- Analyst Count
- RMBI 0
- KLRS 1
- Target Price
- RMBI N/A
- KLRS N/A
- AVG Volume (30 Days)
- RMBI 37.4K
- KLRS 56.9K
- Earning Date
- RMBI 04-24-2025
- KLRS 05-27-2025
- Dividend Yield
- RMBI 4.27%
- KLRS N/A
- EPS Growth
- RMBI 2.54
- KLRS N/A
- EPS
- RMBI 0.89
- KLRS N/A
- Revenue
- RMBI $42,825,048.00
- KLRS N/A
- Revenue This Year
- RMBI N/A
- KLRS N/A
- Revenue Next Year
- RMBI N/A
- KLRS N/A
- P/E Ratio
- RMBI $15.88
- KLRS N/A
- Revenue Growth
- RMBI 2.64
- KLRS N/A
- 52 Week Low
- RMBI $10.88
- KLRS $4.19
- 52 Week High
- RMBI $15.15
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- RMBI 62.70
- KLRS N/A
- Support Level
- RMBI $13.60
- KLRS N/A
- Resistance Level
- RMBI $14.30
- KLRS N/A
- Average True Range (ATR)
- RMBI 0.46
- KLRS 0.00
- MACD
- RMBI 0.01
- KLRS 0.00
- Stochastic Oscillator
- RMBI 94.44
- KLRS 0.00
About RMBI Richmond Mutual Bancorporation Inc.
Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.